Acute Respiratory Distress Syndrome Management

Initial Respiratory Support Strategy

For patients with mild ARDS, the American Thoracic Society recommends considering a trial of high-flow nasal cannula starting at 30-40 L/min with FiO₂ 50-60% only in hemodynamically stable, alert, cooperative patients without pneumonia as the ARDS etiology 1
The American College of Chest Physicians suggests proceeding to intubation in a controlled setting if deterioration occurs within 1 hour, FiO₂ exceeds 70%, or flow exceeds 50 L/min 2, 1

The Society of Critical Care Medicine recommends setting tidal volume at 4-8 mL/kg predicted body weight and maintaining plateau pressure ≤30 cmH₂O at all times 2, 1
The American Thoracic Society suggests applying higher PEEP in moderate-to-severe ARDS using the ARDS-network PEEP-to-FiO₂ grid, monitoring for hemodynamic compromise 2, 1

The American College of Chest Physicians recommends targeting SpO₂ 92-96% and PaO₂ 70-90 mmHg 2, 1

The Society of Critical Care Medicine suggests implementing conservative fluid management to minimize pulmonary edema while maintaining adequate organ perfusion 2, 1

The American Thoracic Society recommends implementing prone positioning for at least 12 hours per day in severe ARDS, as this has demonstrated significant mortality reduction 2, 1
The European Society of Intensive Care Medicine suggests considering cisatracurium infusion for 24-48 hours after ARDS onset in severe ARDS to improve ventilator synchrony, reduce oxygen consumption, and potentially improve outcomes 2, 1

The European Respiratory Society recommends rapidly identifying and treating the underlying etiology, as this is the only causal treatment measure 3
For COVID-19 pneumonia, the National Institutes of Health suggests dexamethasone has proven effective 3

The American College of Chest Physicians recommends monitoring oxygen saturation, respiratory mechanics, and hemodynamics continuously 2, 1
The Society of Critical Care Medicine suggests assessing right ventricular function via echocardiography, as RV failure significantly worsens outcomes 2, 1

The European Respiratory Society warns that excessive fluid administration, blood product transfusions, and injurious mechanical ventilation can aggravate lung injury 3, 4
The American Thoracic Society recommends establishing a diagnostic protocol to identify treatable diseases that mimic ARDS, as these require specific therapies rather than standard ARDS management 5

Low‑tidal‑volume ventilation (4–8 mL/kg predicted body weight) is the only ventilatory approach that has consistently demonstrated a protective effect across all ARDS patients – high‑quality randomized evidence. 6
Higher PEEP levels improve oxygenation and outcomes in selected ARDS subgroups but can cause harm in others; therefore continuous hemodynamic monitoring is required when applying higher PEEP – moderate‑quality evidence. 7
Patients who require endotracheal intubation after a failed trial of non‑invasive support (e.g., high‑flow nasal cannula) experience significantly worse clinical outcomes – observational cohort data. 7

A conservative fluid‑management strategy that limits unnecessary fluid administration reduces pulmonary edema and is associated with better organ‑perfusional balance – moderate‑quality evidence. 6
Excessive fluid administration acts as a “second hit” that aggravates lung injury and is linked to higher mortality in ARDS – moderate‑quality evidence. 6
Transfusion of blood products is associated with increased mortality and should be avoided unless clearly indicated – moderate‑quality evidence. 6

Ventilation with high tidal volumes or plateau pressures >30 cmH₂O is injurious and independently associated with increased mortality in ARDS – moderate‑quality evidence. 6

Systemic glucocorticoids have not shown a mortality benefit in general ARDS populations; they are only recommended for COVID‑19‑related ARDS or when fibroproliferation is strongly suspected – moderate‑quality evidence. 7